Abstracts tagged "risk factors"

Abstract Number: 2052 • ACR Convergence 2023
Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
Qianzi Zhao¹, Beth Wallace², Lawrence Jung³ and Tova Ronis⁴, ¹Trinity Health Ann Arbor, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Jung Medical, Cedar Falls, IA, ⁴Children's National Hospital, Chevy Chase, MD
Background/Purpose: Among adults who develop SARS-CoV-2 infection, those with rheumatic diseases (RDs) have similar hospitalization rates compared to those without RDs. Similar comparisons are lacking…
Abstract Number: 2530 • ACR Convergence 2023
Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center
Sarah Keller¹, Adil Vural², Jennifer Varley², Komal Mushtaq², Walaa Abu Alya³, Neel Tapryal², Hassan Shaheen³, Marie Budev², Abby Abelson² and Chad Deal¹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Fairview Hospital, Cleveland, OH
Background/Purpose: Osteoporotic fractures are a well-known complication in LT recipients, significantly impacting their quality of life. Specific risk factors for these fractures in LT recipients…
Abstract Number: 0176 • ACR Convergence 2023
Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Social determinants of health (SDOH) have a significant impact on the health outcomes of many chronic conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
Abstract Number: 0740 • ACR Convergence 2023
Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease
Shivani Garg¹, Brad Astor², S. Sam Lim³, Amish Raval², Weixiong Zhong², Sarah Panzer², Brad Rovin⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³Emory University, Atlanta, GA, ⁴Ohio State University, Columbus, OH
Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators…
Abstract Number: 1374 • ACR Convergence 2023
Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival
Marco Sprecher¹, Florine Weber², Kastriot Kastrati³, Helmut Prosch⁴, Natasha Moe⁵, Emily Langballe⁶, Cosimo Bruni⁷, Oyvind Molberg⁸, Phuong Phuong Diep⁹, Christian Clarenbach¹⁰, Paul Studenic¹¹, Helena Andersson⁸, Oyvind Midtvedt¹², Torhild Garen⁸, Karoline Lerang¹³, Thomas Frauenfelder¹⁴, Helga Radner¹⁵, Oliver Distler⁷ and Anna Maria Hoffmann-Vold¹⁶, ¹Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ⁴Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁵Dept of Radiology, University Hospital Oslo, Oslo, Norway, ⁶Universitetet i Oslo, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ¹⁰Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹¹Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁴Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹⁵Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁶Oslo University Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) has been reported to be present in 10-15% of patients with primary Sjögren's syndrome (pSS). Knowledge on risk factors predicting…
Abstract Number: 2104 • ACR Convergence 2023
Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², yoshifumi Ohashi², Shuji Asai² and Shiro Imagama², ¹Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a causative factor in frailty. Large joint symptoms in RA patients may be more strongly associated with physical disability than…
Abstract Number: 2533 • ACR Convergence 2023
Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka², Eisuke Inoue³, Mai Abe¹, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai⁴, Rei Yamaguchi¹, Katsunori Ikari⁵, Ayako Nakajima⁶, Hisashi Yamanaka⁷ and Masayoshi Harigai⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjunku-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine,, Shinjunku-ku, Japan, ⁵Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁷Sanno Medical Center, Tokyo, Japan, ⁸Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have been reported to have higher mortality rates than the general population. Our previous report showed that the standardized…
Abstract Number: 0185 • ACR Convergence 2023
Classifying Individuals with Rheumatic Conditions as Financially Insecure Using Electronic Health Record Data and Natural Language Processing: Algorithm Derivation and Validation
Mia Chandler¹, Tianrun Cai², Leah Santacroce², Sciaska Ulysse², Katherine Liao² and Candace Feldman², ¹Boston Children's Hospital, Milton, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Social determinants of health (SDoH) such as financial insecurity contribute to disparities in rheumatic disease care and outcomes but are not routinely included in…
Abstract Number: 0816 • ACR Convergence 2023
Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout and Nephrolithiasis, a Hospital-Based, Case-Control Study
Ching-Tsai Lin¹, I-Chieh Chen², Wen-Nan Huang¹, Yi-Hsing Chen¹, Ching-Heng Lin² and Yi-Ming Chen¹, ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: This study aimed to investigate the interaction between the ABCG2 rs4148155 and SLC22A12 rs75786299 variants and their association with incident gout and nephrolithiasis in…
Abstract Number: 1394 • ACR Convergence 2023
Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Bon San Koo¹, Subin Hwang¹, Ye-Jee Kim², Soo Min Ahn² and Wook Jang Seo³, ¹Inje University Seoul Paik Hospital, Seoul, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…
Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Sayuli Bhide¹, Punyasha Roul², Namrata Singh³, Grant Cannon⁴, Gary Kunkel⁵, Ted R Mikuls⁶, Bryant England², Dolores Shoback⁷, Patti Katz⁸, Jose Garcia⁹, Ariela Orkaby¹⁰, Joshua Baker¹¹ and K Wysham¹², ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷San Francisco VA Medical Center, San Francisco, CA, ⁸University of California San Francisco, San Rafael, CA, ⁹VA Puget Sound Healthcare System, Seattle, WA, ¹⁰Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…
Abstract Number: 2536 • ACR Convergence 2023
DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection
Tanya Selvam, Kelli Peterman, Arezoo Haghshenas and Lucy Liu, Kaiser Permanente Northern California, Oakland, CA
Background/Purpose: The COVID-19 pandemic affected medication adherence in patients with autoimmune disease (AD) due to their fear of contracting COVID-19, financial hardship, and medication shortage.…
Abstract Number: 0211 • ACR Convergence 2023
COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study
Hilde Ørbo¹, Ingrid Jyssum¹, Joseph Sexton¹, Anne Therese Tveter¹, Ingrid Christensen¹, Kristin Hammersbøen Bjørlykke², Grete B. Kro³, Tore Kvien¹, Ludvig A. Munthe⁴, Gunnveig Grødeland⁵, Siri Mjaaland⁶, Espen Haavardsholm¹, John Torgils Vaage⁴, Kristin Kaasen Jørgensen², Sella Provan⁷, Silje Watterdal Syversen¹ and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁵Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁶Norwegian Institute of Public Health, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated vaccine responses and are prone to severe infections. Knowledge of COVID-19 outcome following…
Abstract Number: 0975 • ACR Convergence 2023
Association of HLA-DRB1 Alleles with Ischemic Events and Mortality in a Multi-ethnic Community-living Population
Manmeet Kaur¹, Ronit Katz², Michael H. Criqui¹, Maripat Corr¹, Wendy S. Post³, Matthew Budoff⁴, Gerald P. Morris⁵ and Jan Hughes-Austin⁵, ¹University of California San Diego, San Diego, CA, ²University of Washington, Seattle, WA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of California Los Angeles, Los Angeles, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Human leukocyte antigen (HLA) DRB1 alleles with specific common amino acids referred to as "the shared epitope (SE)", have been linked to cardiovascular mortality…
Abstract Number: 1604 • ACR Convergence 2023
First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Yasaman Ahmadzadeh², Danieli Andrade³, leslie skeith⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Denis WAHL¹⁴, Maria Gerosa¹⁵, Guilherme De Jesús¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Laura Andreoli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁷, Guillermo Pons-Estel²⁸, Rohan Willis²⁹, Ali Duarte-Garcia³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Doruk Erkan¹ and On Behalf Of APS ACTION³³, ¹Hospital for Special Surgery, New York, NY, ²Roger Williams Medical Center, Providence, RI, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Milan, Milano, Italy, ¹⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷University of Michigan, Ann Arbor, MI, ²⁸CREAR, Rosario, Argentina, ²⁹University of Texas Medical Branch, Galveston, TX, ³⁰Mayo Clinic, Rochester, MN, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³on behalf of APS ACTION, New York, NY
Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…

« Previous Page
1
…
6
7
8
9
10
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].